JP2020514689A - 膵管腺癌の検出および処置のための方法 - Google Patents

膵管腺癌の検出および処置のための方法 Download PDF

Info

Publication number
JP2020514689A
JP2020514689A JP2019531802A JP2019531802A JP2020514689A JP 2020514689 A JP2020514689 A JP 2020514689A JP 2019531802 A JP2019531802 A JP 2019531802A JP 2019531802 A JP2019531802 A JP 2019531802A JP 2020514689 A JP2020514689 A JP 2020514689A
Authority
JP
Japan
Prior art keywords
antigen
patient
timp1
lrg1
biological sample
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019531802A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020514689A5 (enExample
Inventor
ハナッシュ サミール
ハナッシュ サミール
カッペロ ミケーラ
カッペロ ミケーラ
タグチ アユム
タグチ アユム
フォン ズディング
フォン ズディング
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Texas System
Original Assignee
University of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Texas System filed Critical University of Texas System
Publication of JP2020514689A publication Critical patent/JP2020514689A/ja
Publication of JP2020514689A5 publication Critical patent/JP2020514689A5/ja
Priority to JP2023011264A priority Critical patent/JP2023055806A/ja
Priority to JP2025080930A priority patent/JP2025118850A/ja
Pending legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57407—Specifically defined cancers
    • G01N33/57438—Specifically defined cancers of liver, pancreas or kidney
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • H—ELECTRICITY
    • H01—ELECTRIC ELEMENTS
    • H01J—ELECTRIC DISCHARGE TUBES OR DISCHARGE LAMPS
    • H01J49/00—Particle spectrometers or separator tubes
    • H01J49/0027—Methods for using particle spectrometers
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4716—Complement proteins, e.g. anaphylatoxin, C3a, C5a
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/81—Protease inhibitors
    • G01N2333/8107—Endopeptidase (E.C. 3.4.21-99) inhibitors
    • G01N2333/8146—Metalloprotease (E.C. 3.4.24) inhibitors, e.g. tissue inhibitor of metallo proteinase, TIMP
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2405/00—Assays, e.g. immunoassays or enzyme assays, involving lipids
    • G01N2405/04—Phospholipids, i.e. phosphoglycerides
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2560/00—Chemical aspects of mass spectrometric analysis of biological material
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/50—Determining the risk of developing a disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N30/00—Investigating or analysing materials by separation into components using adsorption, absorption or similar phenomena or using ion-exchange, e.g. chromatography or field flow fractionation
    • G01N30/02—Column chromatography
    • G01N30/62—Detectors specially adapted therefor
    • G01N30/72—Mass spectrometers
    • G01N30/7233—Mass spectrometers interfaced to liquid or supercritical fluid chromatograph

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Urology & Nephrology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biotechnology (AREA)
  • Pathology (AREA)
  • Food Science & Technology (AREA)
  • Oncology (AREA)
  • Physics & Mathematics (AREA)
  • Hospice & Palliative Care (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
JP2019531802A 2016-12-15 2017-12-15 膵管腺癌の検出および処置のための方法 Pending JP2020514689A (ja)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP2023011264A JP2023055806A (ja) 2016-12-15 2023-01-27 膵管腺癌の検出および処置のための方法
JP2025080930A JP2025118850A (ja) 2016-12-15 2025-05-14 膵管腺癌の検出および処置のための方法

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662435020P 2016-12-15 2016-12-15
US201662435024P 2016-12-15 2016-12-15
US62/435,024 2016-12-15
US62/435,020 2016-12-15
PCT/US2017/066851 WO2018112428A1 (en) 2016-12-15 2017-12-15 Methods for the detection and treatment of pancreatic ductal adenocarcinoma

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2023011264A Division JP2023055806A (ja) 2016-12-15 2023-01-27 膵管腺癌の検出および処置のための方法

Publications (2)

Publication Number Publication Date
JP2020514689A true JP2020514689A (ja) 2020-05-21
JP2020514689A5 JP2020514689A5 (enExample) 2021-02-04

Family

ID=62559366

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2019531802A Pending JP2020514689A (ja) 2016-12-15 2017-12-15 膵管腺癌の検出および処置のための方法
JP2023011264A Pending JP2023055806A (ja) 2016-12-15 2023-01-27 膵管腺癌の検出および処置のための方法
JP2025080930A Pending JP2025118850A (ja) 2016-12-15 2025-05-14 膵管腺癌の検出および処置のための方法

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2023011264A Pending JP2023055806A (ja) 2016-12-15 2023-01-27 膵管腺癌の検出および処置のための方法
JP2025080930A Pending JP2025118850A (ja) 2016-12-15 2025-05-14 膵管腺癌の検出および処置のための方法

Country Status (6)

Country Link
US (3) US20200182876A1 (enExample)
EP (1) EP3555628A4 (enExample)
JP (3) JP2020514689A (enExample)
KR (1) KR102549063B1 (enExample)
CN (1) CN110121647A (enExample)
WO (1) WO2018112428A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025508376A (ja) * 2022-02-15 2025-03-26 カイト ファーマ インコーポレイテッド 免疫療法由来の有害事象の予測

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3064940B1 (en) * 2013-10-28 2019-07-03 Salivatech Co., Ltd. Salivary biomarker for pancreatic cancer
CN110646554B (zh) * 2019-09-12 2022-05-13 北京博远精准医疗科技有限公司 基于代谢组学的胰腺癌诊断标志物及其筛选方法和应用
RU2745793C1 (ru) * 2020-02-26 2021-04-01 Государственное бюджетное учреждение здравоохранения города Москвы городская клиническая больница имени С.П. Боткина департамента здравоохранения города Москвы (ГБУЗ ГКБ им. С.П. Боткина ДЗМ) Способ расчета средней продолжительности жизни у пациентов с метастатической аденокарциномой поджелудочной железы
CN115125312B (zh) * 2021-03-26 2025-07-18 中国科学院上海营养与健康研究所 用于Basal型胰腺导管腺癌(PDAC)诊断的标志物组合及其应用
CN113777309A (zh) * 2021-09-07 2021-12-10 复旦大学附属肿瘤医院 自身抗体在制备胰腺导管腺癌诊断试剂盒中的应用
CN113917008A (zh) * 2021-09-09 2022-01-11 广州济士源生物技术有限公司 质谱检测尿液中代谢物水平的产品在制备用于早期评估肠道息肉和结直肠癌产品中的应用
CN114487201A (zh) * 2022-02-09 2022-05-13 江西省肿瘤医院(江西省第二人民医院、江西省癌症中心) 鼻咽癌相关尿液标志物组合的检测试剂的应用
WO2024059549A2 (en) * 2022-09-12 2024-03-21 Board Of Regents, The University Of Texas System Methods for the detection and treatment of pancreatic ductal adenocarcinoma

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
JP2013506142A (ja) * 2009-10-01 2013-02-21 フェノメノーム ディスカバリーズ インク 膵臓癌の血清ベースのバイオマーカー並びに疾患検出及び診断のためのその使用
US20140271621A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
WO2015064594A1 (ja) * 2013-10-28 2015-05-07 学校法人 慶應義塾 癌用唾液バイオマーカー、その測定方法、装置、及び、癌用唾液バイオマーカーの特定方法
JP2016538530A (ja) * 2014-10-17 2016-12-08 エスケーテレコム カンパニー リミテッドＳｋ Ｔｅｌｅｃｏｍ Ｃｏ．， Ｌｔｄ． 膵臓癌診断用組成物およびこれを用いた膵臓癌診断方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2012343843B2 (en) * 2011-11-30 2018-03-08 Metanomics Health Gmbh Device and methods to diagnose pancreatic cancer
AU2014368412A1 (en) * 2013-12-20 2016-07-07 Metanomics Health Gmbh Means and methods for diagnosing pancreatic cancer in a subject based on a metabolite panel

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100092476A1 (en) * 2006-11-17 2010-04-15 Hanash Samir M Pancreatic cancer biomarkers
JP2013506142A (ja) * 2009-10-01 2013-02-21 フェノメノーム ディスカバリーズ インク 膵臓癌の血清ベースのバイオマーカー並びに疾患検出及び診断のためのその使用
US20140271621A1 (en) * 2013-03-14 2014-09-18 Abbott Laboratories Methods of prognosis and diagnosis of pancreatic cancer
WO2015064594A1 (ja) * 2013-10-28 2015-05-07 学校法人 慶應義塾 癌用唾液バイオマーカー、その測定方法、装置、及び、癌用唾液バイオマーカーの特定方法
JP2016538530A (ja) * 2014-10-17 2016-12-08 エスケーテレコム カンパニー リミテッドＳｋ Ｔｅｌｅｃｏｍ Ｃｏ．， Ｌｔｄ． 膵臓癌診断用組成物およびこれを用いた膵臓癌診断方法

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
BRAND, R. E. ET AL.: "Serum Biomarker Panels for the Detection of Pancreatic Cancer", CLINICAL CANCER RESEARCH, vol. 17, no. 4, JPN6021051991, 15 February 2011 (2011-02-15), pages 805 - 816, ISSN: 0004672923 *
CAPELLO, M. ET AL.: "Sequential Validation of Blood-Based Protein Biomarker Candidates for Early-Stage Pancreatic Cancer", JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 109, no. 4, JPN6021051988, 17 December 2016 (2016-12-17), pages 1 - 9, ISSN: 0004672925 *
FAHRMANN J, F. ET AL.: "A Plasma-Derived Protein-Metabolite Multiplexed Panel for Early-Stage Pancreatic Cancer", JNCI: JOURNAL OF THE NATIONAL CANCER INSTITUTE, vol. 111, no. 4, JPN6021051983, 18 August 2018 (2018-08-18), pages 372 - 379, ISSN: 0004672926 *
PAN, S. ET AL.: "Protein Alterations Associated with Pancreatic Cancer and Chronic Pancreatitis Found in Human Plasma", JOURNAL OF PROTEOME RESEARCH, vol. 10, no. 5, JPN6021051989, 12 March 2011 (2011-03-12), pages 2359 - 2376, ISSN: 0004672924 *
PORUK, K. E. ET AL.: "Serum osteopontin and tissue inhibitor of metalloproteinase 1 as diagnostic and prognostic biomarker", PANCREAS, vol. 42, no. 2, JPN6021051980, March 2013 (2013-03-01), pages 193 - 197, ISSN: 0004672922 *
YANG, J. Y. ET AL.: "Novel biomarker panel for the early detection of pancreatic cancer and its clinical validation", HPB, vol. Vol.18, Supplement 1, JPN6021051978, 1 April 2016 (2016-04-01), pages 44, ISSN: 0004672921 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2025508376A (ja) * 2022-02-15 2025-03-26 カイト ファーマ インコーポレイテッド 免疫療法由来の有害事象の予測

Also Published As

Publication number Publication date
KR102549063B1 (ko) 2023-06-28
US20230324394A1 (en) 2023-10-12
JP2025118850A (ja) 2025-08-13
US20250298025A1 (en) 2025-09-25
EP3555628A1 (en) 2019-10-23
CN110121647A (zh) 2019-08-13
KR20190101395A (ko) 2019-08-30
JP2023055806A (ja) 2023-04-18
US20200182876A1 (en) 2020-06-11
EP3555628A4 (en) 2020-08-05
WO2018112428A1 (en) 2018-06-21

Similar Documents

Publication Publication Date Title
US20250298025A1 (en) Methods for the detection and treatment of pancreatic ductal adenocarcinoma
JP6082026B2 (ja) 肺癌診断用の組成物、方法及びキット
JP2023545017A (ja) 肺がんの検出及び治療のための方法
WO2012015904A2 (en) Biomarkers for prostate cancer and methods using the same
Chen et al. Comparison of membrane fraction proteomic profiles of normal and cancerous human colorectal tissues with gel‐assisted digestion and iTRAQ labeling mass spectrometry
US20240151732A1 (en) Ex vivo method for analysing a tissue sample using proteomic profile matching, and its use for the diagnosis, prognosis of pathologies and for predicting response to treatments
CN110291397A (zh) 肺癌的检测和治疗方法
Chinello et al. The proteomic landscape of renal tumors
WO2019079635A1 (en) COMPOSITIONS, METHODS AND KITS FOR THE DIAGNOSIS OF LUNG CANCER
Giusti et al. Comparative proteomic analysis of malignant pleural mesothelioma evidences an altered expression of nuclear lamin and filament‐related proteins
CN120188046A (zh) 鉴定胰腺癌的方法
EP2876445A1 (en) Method for in vitro diagnosing and prognosing of triple negative breast cancer recurrence
Bhat et al. Combined proteomic/transcriptomic signature of recurrence post-liver transplantation for hepatocellular carcinoma beyond Milan
Song et al. MALDI‐TOF‐MS analysis in low molecular weight serum peptidome biomarkers for NSCLC
White et al. Quantitative mass spectrometry to identify protein markers for diagnosis of malignant pleural mesothelioma
Kovacevic et al. Urine proteomic analysis in cystinuric children with renal stones
Cai et al. Diagnosis and prognosis prediction of gastric cancer by high-performance serum lipidome fingerprints
US20250273344A1 (en) Methods for the detection and treatment of lung cancer
Vareed et al. Metabolites of purine nucleoside phosphorylase (NP) in serum have the potential to delineate pancreatic adenocarcinoma
US20220178924A1 (en) Systems and methods for identifying subtype, prognosis, and monitoring of breast cancer
US20190339286A1 (en) Method to determine braf mutations and wild type braf protein by mass spectrometry
Uemura et al. Current status of proteomics of esophageal carcinoma
Paolino et al. The fatty acid and protein profiles of circulating CD81-positive small extracellular vesicles are associated with disease stage in melanoma patients. Cancers (Basel). 2021; 13
Rakhshan et al. Applications of mass spectroscopy in understanding cancer proteomics
Stella Identification of molecular alterations associated with the progression of clear cell Renal Cell Carcinoma by mass spectrometric approaches

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201215

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201215

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20211122

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20220104

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20220322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20220603

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220927

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20230127

C60 Trial request (containing other claim documents, opposition documents)

Free format text: JAPANESE INTERMEDIATE CODE: C60

Effective date: 20230127

C11 Written invitation by the commissioner to file amendments

Free format text: JAPANESE INTERMEDIATE CODE: C11

Effective date: 20230221

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20230320

C21 Notice of transfer of a case for reconsideration by examiners before appeal proceedings

Free format text: JAPANESE INTERMEDIATE CODE: C21

Effective date: 20230322

A912 Re-examination (zenchi) completed and case transferred to appeal board

Free format text: JAPANESE INTERMEDIATE CODE: A912

Effective date: 20230512

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241003